Aqueous solubility enhancement through engineering of binary solid composites: Pharmaceutical applications

Journal of Pharmaceutical Innovation

Volumn 4, Issue 1, 2009, Pages 36-49

  Moore, Michael D ^a   Wildfong, Peter L D ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

Amorphous dispersions; Composite materials; Eutectic solids; Solubility enhancement

Indexed keywords

DRUG; MACROGOL; POLYMER;

AQUEOUS SOLUTION; CHEMICAL MODIFICATION; CRYSTALLIZATION; DISPERSION; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; PARTICLE SIZE; PHARMACEUTICAL ENGINEERING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SOLID STATE; THERMODYNAMICS;

EID: 63949088026     PISSN: 18725120     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12247-009-9053-7     Document Type: Review

References (80)

1. Amidon GL, et al. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12(3):413-20.
2. Fleisher D, Bong R, Stewart BH. Improved oral drug delivery: Solubility limitations overcome by the use of prodrugs. Adv Drug Deliv Rev 1996;19:115-30.
3. Morris KR, et al. An integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm 1994;105(3):209-17.
4. Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Deliv Rev 2007;59:603-13.
5. Sinko PJ. Martin's physical pharmacy and pharmaceutical sciences. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
6. Krise JP, Narisawa S, Stella VJ. A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs. J Pharm Sci 1999;88(9):922-7.
7. Noyes AA, Whitney WR. The rate of dissolution of solid substances in their own solutions. J Am Chem Soc 1897;19:930-4.
8. Byrn SR, Pfeiffer RR, Stowell JG. Solid state chemistry of drugs. 2nd ed. West Lafayette: SSCI; 1999.
9. Wildfong PLD, et al. Demonstration of a shear-based solid-state phase transformation in a small molecular organic system: Chlorpropamide. J Pharm Sci 2007;96(5):1100-13.
10. Lin Y, Cogdill RP, Wildfong PLD. Informatic calibration of a materials properties database for predictive assessment of mechanically activated disordering potential for small molecule organic solids. J Pharm Sci 2009. doi: 10.1002/jps.21647.
11. Wildfong PLD, et al. Towards an understanding of the structurally based potential for mechanically activated disordering of small molecule organic crystals. J Pharm Sci 2006;95(12):2645-56.
12. Zhang GGZ, et al. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Deliv Rev 2004;56:371-90.
13. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996;85(10):1017-25.
14. Li P, Zhao L. Developing early formulations: Practice and perspective. Int J Pharm 2007;341:1-19.
15. Kaushal AM, Gupta P, Bansal AK. Amorphous drug delivery systems: molecular aspects, design, and performance. Crit Rev Ther Drug Carr Syst 2004;21:133-93.
16. Porter DA, Easterling KE. Phase transformations in metals and alloys. New York: Van Nostrand Reinhold; 1981.
17. Woolliams ER, et al. Metal (carbide)-carbon eutectics for thermometry and radiometry: A review of the first seven years. Metrologia 2006;43:R11-25.
18. Askeland DR, Phule PP. The science and engineering of materials. 5th ed. Toronto: Thompson; 2006.
19. Bansal SS, Kaushal AM, Bansal AK. Molecular and thermodynamic aspects of solubility advantage from solid dispersions. Mol Pharm 2007;4(5):794-802.
20. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47-60.
21. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999;88(10):1058-66.
22. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007;12(23/24):1068-75.
23. Kukushkin SA, Grigoriev DA. Theory of the late-stage crystallization of eutectic composition melts. J Phys Chem Solids 2000;61:1337-43.
24. Margarit MV, Marin MT, Contreras MD. Solubility of solid dispersions of pizotifen malate and povidone. Drug Dev Ind Pharm 2001;27(6):517-22.
25. Nazzal S, et al. Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: Mechanism and progress of emulsion formation. Int J Pharm 2002;235:247-65.
26. Rombach E, Ulrich J. Self-controlled coating process for drugs. Cryst Growth Des 2007;7(9):1618-22.
27. Sakata Y, et al. Effects of solid-state reaction between paracetamol and cloperastine hydrochloride on the pharmaceutical properties of their preparations. Int J Pharm 2007;335:12-9.
28. Meng G, Lin X, Huang W. The relationship between effective entropy change and volume fraction of the eutectic phases in eutectic microstructures. Mater Lett 2008;62:984-7.
29. Hunt JD, Jackson KA. Binary eutectic solidification. Trans Metall Soc AIME 1966;236(6):843-52.
30. Law D, et al. Properties of rapidly dissolving eutectic mixtures of poly(ethylene glycol) and fenofibrate: The eutectic microstructure. J Pharm Sci 2003;92(3):505-15.
31. Yong CS, et al. Preparation of ibuprofen-loaded liquid suppository using eutectic mixture system with menthol. Eur J Pharm Sci 2004;23:347-53.
32. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersions. J Pharm Sci 1971;60:1281-302.
33. Qi S, et al. Characterisation of solid dispersions of paracetamol and Eudragit E prepared by hot-melt extrusion using thermal, microthermal and spectroscopic analysis. Int J Pharm 2008;354:158-67.
34. Konno H, Taylor LS. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 2006;95(12):2692-705.
35. Miyazaki T, et al. Ability of polyvinylpyrrolidone and polyacrylic acid to inhibit the crystallization of amorphous acetaminophen. J Pharm Sci 2004;93:2710-7.
36. Tang XC, Pikal MJ, Taylor LS. A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers. Pharm Res 2002;19:477-83.
37. Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 1997;14:1691-8.
38. Waard Hd, et al. Unexpected differences in dissolution behavior of tablets prepared from solid dispersions with a surfactant physically mixed or incorporated. Int J Pharm 2008;349:66-73.
39. Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 2002;231:131-44.
40. Karavas E, et al. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm 2007;66:334-47.
41. Anguiano-Igea S, et al. The properties of solid dispersions of clofibrate in polyethylene glycols. Pharm Acta Helv 1995;70:57-66.
42. Docoslis A, et al. Characterization of the distribution, polymorphism, and stability of nimodipine in its solid dispersions in polyethylene glycol by micro-Raman spectroscopy and powder X-ray diffraction. AAPS J 2007;9(3):361-70.
43. Law D, et al. Physicochemical considerations in the preparation of amorphous ritonavir-poly(ethylene glycol) 8000 solid dispersions. J Pharm Sci 2001;90(8):1015-25.
44. Sekiguchi K, Obi N. Studies on absorption of eutectic mixtures. I. A comparison of the behavior of eutectic mixtures of sulphathiazole and that of ordinary sulphathiazole in man. Chem Pharm Bull 1961;9:866-72.
45. Tachibana T, Nakamura A. A method for preparing an aqueous colloidal dispersion of organic materials by using water-soluble polymers: dispersion of beta-carotene by polyvinylpyrrolidone. Colloid Polym Sci 1965;203:130-3.
46. Lacoulonche F, Chauvet A, Masse J. An investigation of flurbiprofen polymorphism by thermoanalytical and spectroscopic methods and a study of its interactions with poly-(ethylene glycol) 6000 by differential scanning calorimetry and modelling. Int J Pharm 1997;153:167-79.
47. Lacoulonche F, et al. An investigation of FB interactions with poly(ethylene glycol) 6000, poly(ethylene glycol) 4000, and poly-e-carpolactone by thermoanalytical and spectroscopic methods and modeling. J Pharm Sci 1998;87(5):543-51.
48. Lheritier J, et al. Improvement of the dissolution kinetics of SR 33557 by means of solid dispersions containing PEG 6000. Int J Pharm 1995;123:273-9.
49. Naima Z, et al. Interactions between carbamazepine and polyethylene glycol (PEG) 6000: Characterisations of the physical, solid dispersed and eutectic mixtures. Eur J Pharm Sci 2001;12:395-404.
50. Stott PW, Williams AC, Barry BW. Transdermal delivery from eutectic systems: Enhanced permeation of a model drug, ibuprofen. J Control Release 1998;50:297-308.
51. Harding LJ, Reading M, Craig DQM. The development of thermally assisted particle manipulation and thermal nanointeraction studies as a means of investigating drug-polymer interactions. J Pharm Sci 2008;97(4):1551-63.
52. Chen Y, et al. Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68. Int J Pharm 2004;286:69-80.
53. Stott PW, Williams AC, Barry BW. Mechanistic study into the enhanced transdermal permeation of a model beta-blocker, propranolol, by fatty acids: A melting point depression effect. Int J Pharm 2001;219:161-76.
54. Yuan X, Capomacchia AC. The binary eutectic of NSAIDs and two-phase liquid system for enhanced membrane permeation. Pharm Dev Technol 2005;1:1-10.
55. Larrea A, Orera VM. Porous crystal structures obtained from directionally solidified eutectic precursors. J Cryst Growth 2007;300:387-93.
56. Mullen JW. Crystallization. 4th ed. Woburn: Reed; 2001.
57. Osborn JC, et al. Proceedings from the 14th International Symposium on Industrial Crystallization. Cambridge, UK; 1999.
58. Bi M, Hwang SJ, Morris KR. Mechanism of eutectic formation upon compaction and its effects on tablet properties. Thermochim Acta 2003;404:213-26.
59. Law D, et al. Prediction of poly (ethylene) glycol-drug eutectic compositions using an index based on the van't Hoff equation. Pharm Res 2002;19(3):315-21.
60. Craig DQM. A review of thermal methods used for the analysis of the crystal form, solution thermodynamics and glass transition behaviour of polyethylene glycols. Thermochim Acta 1995;248:189-203.
61. Newa M, et al. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. Int J Pharm 2007;343:228-37.
62. Smikalla MM, Urbanetz NA. The influence of povidone K17 on the storage stability of solid dispersions of nimodipine and polyethylene glycol. Eur J Pharm Biopharm 2007;66:106-12.
63. Huang J, Wigent RJ, Schwartz JB. Drug-polymer interaction and its significance on the physical stability of nifedipine amorphous dispersion in microparticles of an ammonio methacrylate copolymer and ethyl cellulose binary blend. J Pharm Sci 2008;97(1):251-62.
64. Janssens S, et al. Physical stability of ternary solid dispersions of itraconazole in polyethylene glycol 6000/hydroxypropylmethylcellulose 2910 E5 blends. Int J Pharm 2008;355:100-7.
65. Zhang X, et al. Physical characterization of lansoprazole/PVP solid dispersion prepared by fluid-bed coating technique. Powder Technol 2008;182:480-5.
66. Chokshi R, Zia H. Hot-melt extrusion technique: A review. Iran J Pharma Res 2004;3:3-16.
67. Papadimitriou SA, Bikiaris D, Avgoustakis K. Microwave-induced enhancement of the dissolution rate of poorly water-soluble tibolone from poly(ethylene glycol) solid dispersions. J Appl Polym Sci 2008;108:1249-58.
68. Xu L, Li SM, Sunada H. Preparation end evaluation of ibuprofen solid dispersion systems with Kollidon particles using a pulse combustion dryer system. Chem Pharm Bull 2007;55(11):1545-50.
69. Sethia S, Squillante E. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int J Pharm 2004;272:1-10.
70. Dong Z, et al. Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation. Int J Pharm 2008;355:141-9.
71. West AR. Basic solid state chemistry. 2nd ed. Hoboken: Wiley; 1999.
72. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997;86(1):1-12.
73. Zhou D, et al. A calorimetric investigation of thermodynamic and molecular mobility contributions to the physical stability of two pharmaceutical glasses. J Pharm Sci 2007;96(1):71-83.
74. Mooter GVd, et al. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci 2001;12:261-9.
75. Marsac PJ, et al. Recrystallization of nifedipine and felodipine from amorphous molecular level solid dispersions containing poly(vinylpyrrolidone) and sorbed water. Pharm Res 2007;25(3):647-56.
76. Gordon M, Taylor JS. Ideal copolymers and the second-order transitions of synthetic rubbers. I. Noncrystalline copolymers. J Appl Chem 1952;2:493-500.
77. Matsumoto T, Zografi G. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization. Pharm Res 1999;16(11):1722-8.
78. Newman A, et al. Characterization of amorphous API: Polymer mixtures using X-ray powder diffraction. J Pharm Sci 2008;97(11):4840-56.
79. Nowers JR, et al. Combinatorial methods and informatics provide insight into physical properties and structure relationships during IPN formation. Macromol Rapid Commun 2007;28:972-6.
80. Rajan K. Materials informatics. Materials Today 2005;8(10):38-45.